Verified factor-similar pair

FSMD vs IVOO

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
88
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • IVOO has the higher backtested relative Sharpe (0.995 vs 0.972).
  • IVOO has the lower published fee (0.07% vs 0.15%).
  • FSMD is cheaper on dividend valuation (111 vs 116, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

FSMD

Fidelity Small-Mid Multifactor ETF
SMB
Adj. R2
0.955
Rel. Sharpe
0.972
Mkt beta
0.94
AUM
US$2.3B
MER
0.15%
Valuation
111

IVOO

Vanguard S&P Mid-Cap 400 ETF
SMB
Adj. R2
0.952
Rel. Sharpe
0.995
Mkt beta
0.99
AUM
US$3.3B
MER
0.07%
Valuation
116

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
FSMD
+0.56
|t|
+10.5
IVOO
+0.49
|t|
+13.8
diff +0.07
HML
FSMD
+0.23
|t|
+5.2
IVOO
+0.18
|t|
+5.1
diff +0.05
RMW
FSMD
+0.15
|t|
+2.8
IVOO
+0.15
|t|
+3.8
diff +0.00
CMA
FSMD
-0.03
|t|
-0.5
IVOO
-0.01
|t|
-0.3
diff -0.02
UMD
FSMD
+0.11
|t|
+3.0
IVOO
+0.03
|t|
+1.0
diff +0.09

Why This Pair Matches

Exposure level
85
Exposure shape
99
Mkt beta diff
0.06
Rel. Sharpe diff
0.023

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

FSMD fund page IVOO fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.